Clinical Trial Update: Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating epcoritamab in combination with tazemetostat for relapsed or refractory follicular lymphoma (Grades I-IIIa) is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Tazemetostat (tazemetostat)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Status: SUSPENDED